Sugi Predict

Sugi Predict / Compounds / SCHEMBL2546283

SCHEMBL2546283

SCHEMBL2546283

O=C(O)c1ccnc(OCCO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 6/20 0.50
▸ KDM5C P41229 5/20 0.50
▸ KDM4E B2RXH2 5/20 0.50
▸ KDM2A Q9Y2K7 4/20 0.50
▸ KDM3A Q9Y4C1 4/20 0.50
▸ KDM4A O75164 4/20 0.50
▸ KDM6B O15054 3/20 0.50
▸ KDM5B Q9UGL1 3/20 0.50
▸ KDM4D Q6B0I6 2/20 0.50
▸ KDM5A P29375 2/20 0.50
▸ TET3 O43151 1/20 0.50
▸ BBOX1 O75936 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ ASPH Q12797 1/20 0.50
▸ TET2 Q6N021 1/20 0.50
▸ ALKBH5 Q6P6C2 1/20 0.50
▸ KDM7A Q6ZMT4 1/20 0.50
▸ KDM8 Q8N371 1/20 0.50
▸ TET1 Q8NFU7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28575456 0.85 CHEK2 (0.44) KDM5CKDM5BGABRPGABRDGABRA1
SCHEMBL25049489 0.85 KDM4C (0.57) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL17412498 0.83 PLA2G2A (0.55) KDM4CKDM5BKDM5AALDH1A1
SCHEMBL30464945 0.83 KDM4C (0.50) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL31729821 0.83 TP53 (0.55) KDM4CKDM5BKDM5A
SCHEMBL2585341 0.83 KDM4C (0.50) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL13490849 0.82 KDM4C (0.49) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL12420736 0.81 KDM5A (0.52) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL12800159 0.81 KDM4C (0.45) KDM4CKDM5CKDM4EKDM2AKDM3A
SCHEMBL1992514 0.81 MAPT (0.57) KDM4CKDM5CKDM4EKDM2AKDM3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113264945-B Spiro derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 — — CN disclosed
CN-113264945-A Spiro derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2021-08-17 — — CN disclosed
EP-2314586-B1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2016-09-14 — — EP disclosed
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 — — US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 — — US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 — — US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 — — US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 — — US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 — — US disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 — — US disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 — — US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 — — US disclosed
EP-2177518-A1 Organic compounds Novartis AG (CH) 2010-04-21 — — EP disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 — — US disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 — — US disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 — — US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 — — EP disclosed
EP-1833816-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Novartis AG (CH) 2007-09-19 — — EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 KDM4C 2839/4885KDM5C 2646/4885KDM4E 1499/4885
US-20110263560-A1 Organic Compounds REN, ACE, OTC KDM4C 404/4885KDM5C 654/4885KDM4E 1140/4885
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 KDM4C 2839/4885KDM5C 2646/4885KDM4E 1499/4885
US-20090312304-A1 ORGANIC COMPOUNDS REN, ACE, PIGO KDM4C 1249/4885KDM5C 1387/4885KDM4E 2265/4885
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 KDM4C 2839/4885KDM5C 2646/4885KDM4E 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback